Stada plans mega exchange: Does the billion dollar treasure come to Frankfurt?

The drug manufacturer Stada is planning a billion -dollar IPO in Frankfurt around Easter 2025. The company, known for products such as Grippostad and Silomat, is preparing to go back to the stock exchange after Bain Capital and Cinven was taken over for 5.3 billion euros in 2017.

Andreas Fibig, a former manager of Bayer and currently a member of the board of Novo Nordisk, will act as an independent Chairman of the Board of Directors of Stada. Peter Goldschmidt remains global CEO. Stada also plans to change the company structure in order to establish a listed corporate holding company under Dutch law, but the seat of which remains in Germany.

IPO with weighing different options

Despite the progress, no final decisions have yet been made; Various options, including a IPO, are considered. It is also unclear how many shares the current owners Bain Capital and Cinven could give.

The headquarters of Stada in Bad Vilbel in the Wetteraukreis remains. A billion -dollar IPO would be a rarity in Germany, since in 2024 only a few companies ventured this step, such as reported.

April 2025 is the realistic goal of returning to the stock exchange, and the industry is eagerly observing these developments. The Frankfurter Neue Presse also has over the planned capital measure reported.